ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "autoimmune diseases"

  • Abstract Number: 0961 • ACR Convergence 2025

    Retinoic acid-related orphan receptor-α: A novel upstream regulator of Hippo signaling and potential therapeutic target in fibrosis

    Cuong Tran-Manh1, Thuong Trinh-Minh2, Christoph Liebel3 and Jörg Distler4, 1Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Nordrhein-Westfalen, Germany, 2Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, 3Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, 4University Hospital Duesseldorf and HHU, Duesseldorf, Germany

    Background/Purpose: Retinoic acid-related orphan receptor-α (RORα) is a nuclear transcription factor implicated in immune regulation, circadian rhythm, and metabolism. However, its role in fibrotic diseases…
  • Abstract Number: 0911 • ACR Convergence 2025

    A Novel FcRn × Albumin Bispecific Antibody Demonstrates Extended Half-life and Deep IgG Reduction in Preclinical Mouse Models

    Hang Su1, Lulu Li1, Zenglin Pei1, Barry Duplantis2, Yuhao Wang2, Yi Li1 and Quan Yu1, 1Ailux, Shanghai, China (People's Republic), 2Ailux, Boston, MA

    Background/Purpose: Autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and Sjögren’s syndrome are characterized by elevated levels of pathogenic autoantibodies that drive inflammation. The…
  • Abstract Number: 0630 • ACR Convergence 2025

    Development, Validation and Performance of a Patient Knowledge Assessment Tool for Assessing the Immediate and Short-term Impact of an Information Course in Systemic Lupus Erythematosus

    Ranjan Gupta, Rudra Prosad Goswami and Anju Mohan, All India Institute of Medical Sciences, New Delhi, Delhi, India

    Background/Purpose: Long-term outcomes in rheumatic diseases can be improved by improving patients’ knowledge, beliefs and perception about their disease. However, there is a lack of…
  • Abstract Number: 0802 • ACR Convergence 2025

    Remission from cutaneous manifestations of lupus with enpatoran, a first-in-class oral small molecule toll-like receptor 7/8 inhibitor: pooled post-hoc exploratory analysis from a randomized placebo-controlled Phase II study

    Eric Morand1, Victoria Werth2, Richard Furie3, Sanjeev Roy4, Ruth Fernandez Ruiz5, Summer Goodson6, Hans Gühring7, Flavie Moreau6 and David Pearson8, 1Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, 2University of Pennsylvania, Philadelphia, PA, 3Division of Rheumatology, Northwell Health, Great Neck, NY, 4Ares Trading SA, an affiliate of Merck KGaA, Darmstadt, Germany, Eysins, Switzerland, 5EMD Serono, Billerica, PA, 6EMD Serono, Billerica, MA, 7The healthcare business of Merck KGaA, Darmstadt, Germany, 8Department of Dermatology, University of Minnesota, Minneapolis, MN

    Background/Purpose: Cutaneous manifestations of lupus are highly prevalent and have a significant impact on patients’ physical and mental health and wellbeing; however, no targeted therapy…
  • Abstract Number: 0361 • ACR Convergence 2025

    Transition in Focus: Health Care Utilization and Disease Status in Youth with Connective Tissue Diseases— A Single-Center Experience in British Columbia, Canada

    Mercedes Chan1, Lori Tucker1, Jude AlMasoud1, Jaime Guzman2, Andrea Human1, David Cabral3, Angela How4, Wendy Wong5 and Jennifer Corpuz6, 1BC Children's Hospital, Vancouver, BC, Canada, 2University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada, 3BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, 4UBC, Vancouver, BC, Canada, 5University of British Columbia, Surrey, BC, Canada, 6UBC, New Westminster, BC, Canada

    Background/Purpose: Graduating from child and family-oriented to adult-oriented health care is a vulnerable time when youth with chronic disease drop out of, or disengage from,…
  • Abstract Number: 0264 • ACR Convergence 2025

    Seeing Beyond the Eye: Subclinical Audio-Vestibular Involvement in Vogt-Koyanagi-Harada Disease

    Mohamed Tharwat Hegazy, Rania Yacoub, Sarah Sheta, Rana Hussein Amin and Noha Khalil, Faculty of Medicine, Cairo University, Cairo, Egypt

    Background/Purpose: Vogt-Koyanagi-Harada disease (VKH) is a systemic disease that affects the central nervous system, ocular, and integumentary system. It causes bilateral granulomatous uveitis, dysacusia ranging…
  • Abstract Number: 0203 • ACR Convergence 2025

    Risk Factors for Cytomegalovirus Infection in Patients Receiving Prolonged High-Dose Corticosteroids for Rheumatic Diseases: A Retrospective Cohort Study

    Sung Ik Cho1, Jin Kyun Park2, Hee Won Cho3, Eun Young Lee4, Eun Bong Lee1 and Jun Won Park1, 1Seoul National University Hospital, Seoul, South Korea, 2Seoul National University College of Medicine, Jongno-gu, Seoul, South Korea, 3Seoul National University, Seoul, Seoul-t'ukpyolsi, Republic of Korea, 4Seoul National University College of Medicine, Seoul, South Korea

    Background/Purpose: Cytomegalovirus (CMV) infection is a well-recognized complication in immunocompromised individuals, yet there islimited evidence guiding surveillance strategies in patients with rheumatic diseases on immunosuppressants.…
  • Abstract Number: 0079 • ACR Convergence 2025

    Association of Protein Arginine Deiminase 4 with the Myosin-9 Motor Complex

    Fatemeh Neela Moadab, Farheen Shaikh, Xiaoxing Wang, cecilia mustelin, Ethan Le, Rayan Najjar, Jie An, Alison Bays and Tomas Mustelin, University of Washington, Seattle, WA

    Background/Purpose: Genetic association data, immunohistochemistry, and functional experiments implicate protein arginine deiminase 4 (PAD4) in the pathogenesis of rheumatoid arthritis (RA). This disease is characterized…
  • Abstract Number: 0008 • ACR Convergence 2025

    Characterization of S-1117, a novel pan-IgG protease engineered for reduced immunogenicity using the IMPACT platform

    Julia Manasson1, Liliana Sanmarco2, Alex Pellerin2, Maria Cecilia Ramello2, Agustin Plasencia2, Jordan Anderson2, Tobias Green2, Andita Newton2, Ryan Peckner2, Yi Xing2, Heather Vital3, Nathan Higginson-Scott2, John Sundy4, Kevin L. Otipoby2 and Ivan Mascanfroni2, 1Seismic Therapeutic, New York, NY, 2Seismic Therapeutic, Watertown, MA, 3Seismic Therapeutic, Lexington, MA, 4Seismic Therapeutic, Durham, NC

    Background/Purpose: Pathogenic autoantibodies are key effectors of inflammation, promoting tissue damage in autoantibody-mediated diseases such as inflammatory myopathies, lupus nephritis, Sjogren’s syndrome, antiphospholipid syndrome, and…
  • Abstract Number: 2699 • ACR Convergence 2025

    Cutaneous IgA Vasculitis: Emulation of a Target Trial from a European Multicentric Retrospective Study

    Elena Biancamaria Mariotti1, Boris Sorin2, William Lutz3, Chloé Grolleau3, Thomas Bettuzzi4, Caterina Ricordi5, Santos Castañeda6, Luisa Herda7, Cord Sunderkotter7, Rodérau Outh8, Romain Paule9, Alexandra Audemard-Verger10, Marzia Caproni11, Angelo Valerio Marzano12, Pietro Quaglino13, Laura Atzori14, Julien Campagne15, Mehemt Erkan16, Nabil Belfeki17, Marijan Frkovic18, Nicolas Dupin19, Raphael Porcher20, Marie Jachiet21 and Benjamin Terrier19, 1University of Florence, Azienda USL Toscana Centro, Department of Dermatology, Florence, Firenze, Italy, 2Assistance Publique Hôpitaux de Paris, Paris, France, 3University Paris Cité, Hospital Saint Louis, Dermatology department, Paris, Paris, France, 4Université Paris Est Créteil Val de Marne, Hôpital Henri-Mondor (APHP), Service de dermatologie, EpiDermE, Paris, France, 5AUSL-IRCCS Reggio Emilia, Parma, Italy, 6Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, 7Department of Dermatology and Venereology, Martin Luther University Halle-Wittenberg, Halle (Saale), Halle, Germany, 8Department of Internal Medicine, Centre Hospitalier de Perpignan, Perpignan, France., Clermont-Ferrand, France, 9Hospital Foch, Service de medicine interne, Suresnes, Paris, Suresnes, France, 10Department of Internal Medicine, Tours University Hospital, Tours, France., Tours, France, 11University of Florence, Azienda USL Toscana Centro, Department of Dermatology, Florence, Florence, Italy, 12Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Milan, Italy, 13University of Turin, Department of Medical Sciences, Section of Dermatology, Turin, Torino, Italy, 14Dermatology Clinic, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Cagliari, Italy, 15Hospital Robert Schuman, Metz, France, 16Hacettepe University Faculty of Medicine Department of Pediatric Rheumatology Ankara, Türkiye, Ankara, Turkey, 17Head of the Internal Medicine and Clinical Immunology Department South Île de France Health Hospital Group, Melun Center, Melun, France, 18Division for clinical immunology and rheumatology, Department of pediatrics UHC Zagreb / School of Medicine Zagreb Croatia, Zagabria, Croatia, 19Cochin Hospital, Paris, France, 20Université Paris Cité and Université Sorbonne Paris Nord, INSERM, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), Paris, France, Paris, France, 21University Paris Cité, Hôpital Saint-Louis, Dermatology department, Paris, Paris, France

    Background/Purpose: Immunoglobulin A vasculitis (IgAV) is a small vessel vasculitis marked by IgA, deposition, palpable purpura with lower body predilection and variable joints, kidney and…
  • Abstract Number: 2580 • ACR Convergence 2025

    Estrogen Modulates Neutrophil Biology: Implications for Autoimmunity

    William Ambler1, Eduardo Patino-Martinez1, Gustaf Wigerblad1, Shuichiro Nakabo2, Jorge Romo-Tena3, Norio Hanata4, James Simone1, Stephen Brooks1, Kan Jiang5, Hong-wei Sun1, Faiza Naz6, Shamima Islam6, Gustavo Gutierrez-Cruz1, Stefania Dell'Orso1, Anshu Deewan7, Vicky Chen7, Paul Schaughency8, Carmelo Carmona-Rivera4, Sarfaraz Hasni1, Veronica Gomez-Lobo9 and Mariana Kaplan4, 1NIH/NIAMS, Bethesda, MD, 2NIAMS, NIH, Bethesda, MD, 3Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 4Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, MD, 5Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, 6National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 7NIH/NIAID, Bethesda, MD, 8NIAID, NIH, Bethesda, MD, 9NIH/NICHD, Bethesda, MD

    Background/Purpose: Neutrophils are essential for inflammation and host defense against infections. Our group has previously highlighted their key roles in the pathogenesis of diseases that…
  • Abstract Number: 2463 • ACR Convergence 2025

    Allogenic anti- CD19 CAR-T cells induce remission in refractory systemic lupus erythematosus

    Chunnei Yang1, Chuanyin Sun2, Binghe Tan3, Chao Hu1, Liyan Wan2, Changling Xie3, Qian Tan3, Mingyao Liu3, Jin Lin2, Bing Du3 and Hongyan Tong1, 1Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China (People's Republic), 2Department of Rheumatology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China (People's Republic), 3BRL Medicine Inc., Shanghai, Shanghai, China (People's Republic)

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease associated with significant morbidity and mortality. The treatment approach for SLE primarily involves immunomodulation and…
  • Abstract Number: 2292 • ACR Convergence 2025

    Safety and Humoral Response to Recombinant Herpes Zoster Vaccine in immunosuppressed Sjögren’s Disease Patients: Results From a Double-Blinded Placebo-Controlled Study

    Sandra G Pasoto1, Talita Ribeiro2, Nadia Emi Aikawa3, Ana C Medeiros-Ribeiro1, Bruno Borges2, Andre Franco4, Henrique Silva2, Eloisa Bonfa5 and Clovis Artur Silva6, 1Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, 2Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, 3Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, São Paulo, Brazil, 4Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Sao Paulo, Brazil, 5Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, 6University of São Paulo, São Paulo, São Paulo, Brazil

    Background/Purpose: Immunosuppressed Sjögren’s disease (SjD) patients are at increased risk of herpes zoster (HZ). Despite this vulnerability, data on safety and immunogenicity of the recombinant…
  • Abstract Number: 1979 • ACR Convergence 2025

    Utility of ALT/AST and Fibrosis-4 Index (FIB-4) Score in Monitoring Methotrexate Hepatotoxicity in Rheumatologic Disease: A Retrospective Analysis

    Julia Wajsberg1, Dana Nachawati2, Lenche Kostadinova3, Donald Anthony4 and Maya Mattar3, 1University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, 2University Hospitals, Cleveland, 3Louis Stolkes Cleveland VA, Cleveland, 4The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH

    Background/Purpose: Methotrexate (MTX) is widely used in rheumatologic disease but carries hepatotoxic risk. Standard monitoring relies on measurement of alanine and aspartate aminotransferase (ALT and…
  • Abstract Number: 1778 • ACR Convergence 2025

    Towards an Earlier and Accurate Diagnosis of Connective Tissue Disease-related Interstitial Lung Disease: TGFB Isoform Genes as Upcoming Biomarkers

    Verónica Pulito Cueto1, Joao Carlos Batista-Liz1, Rebeca Nieto-Nieto2, Clara Vaquera-Illescas2, Diego San Emeterio-Villar2, Daniel Vicente-Mínguez2, María Sebastián Mora-Gil2, Belén Atienza-mateo3, Ana Serrano-Combarro4, David Iturbe-Fernández5, Victor M. Mora-Cuesta5, Carolina Aguirre-Portilla4, Jose M Cifrián5, Ricardo Blanco4 and Raquel Lopez Mejias1, 1IDIVAL, Santander, Spain, 2Immunopathology Group, IDIVAL, Santander, Spain, 3Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, PALMA DE MALLORCA/BALEARES, Spain, 4Immunopathology Group, IDIVAL and Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 5Immunopathology Group, IDIVAL and Division of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain

    Background/Purpose: Interstitial lung disease (ILD) is one of the leading cause of mortality in patients with connective tissue diseases (CTDs) [1]. The onset of CTD-ILD…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 101
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology